-+ 0.00%
-+ 0.00%
-+ 0.00%

Evommune's pre-market share price fell 18.1%. Previously, the eczema drug developed by the company did not reach the main end of the mid-term trial.

Zhitongcaijing·09/09/2026 08:09:27
Listen to the news
Evommune's pre-market share price fell 18.1%. Previously, the eczema drug developed by the company did not reach the main end of the mid-term trial.